Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 483

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 483
---
, into 12,488 shares of New Semnur Common Stock (the “Scilex Note Shares”) in connection with the Closing of the Business Combination. The Scilex Note Shares were issued by the Company to Scilex in reliance upon the provisions of Section 4(a)(2) of the Securities Act or Rule 506(b) of Regulation D promulgated by the SEC under the Securities Act. |

| • |     | On September 23, 2025 we entered into the Biconomy SPA with Biconomy. Pursuant to the Biconomy SPA, we agreed to issue and sell, and Biconomy agreed to purchase, an aggregate of 6,250,000 shares of Common Stock, for a purchase price of $16.00 per share, payable in Bitcoin, with such amount of Bitcoin equal to the quotient of (A) the Buyer’s respective aggregate Purchase Price divided by (B) the spot exchange rate for Bitcoin as published by Coinbase.com at 8:00 p.m. (New York City time) on the trading day immediately prior to the closing date of the purchase. Upon the closing of the transactions contemplated by the Biconomy SPA, the Biconomy Shares will be issued by the Company to Biconomy in reliance upon the provisions of Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated by the SEC under the Securities Act. |

II-3

Exhibits and Financial Statements Schedules

| Exhibit 
 Number  
 2.1#    
 2.2     |     | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
 Agreement and Plan of Merger, dated as of March 18, 2019, by and among Scilex Holding Company, Sigma Merger Sub, Inc., Semnur Pharmaceuticals, Inc., Fortis Advisors LLC, solely as the representative of the Equityholders and, solely with respect to Section 1.8(a), Section 3.11 and Article X, Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of Denali’s registration statement on Form S-4 filed with the SEC on August 12, 2025).                                                 
 Amendment No. 1 to Agreement and Plan of Merger, dated as of August 7, 2019, by and among Semnur Pharmaceuticals, Inc., Scilex Holding Company, Sigma Merger Sub, Inc., Fortis Advisors, LLC, solely